Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
pCR bij gereseceerd pancreasadenocarcinoom na preoperatieve chemo(radio)therapie
sep 2024 | Maag-darm-leveroncologie